Omega-3 ethylester concentrate - Pronova BioPharma
Alternative Names: Esapent; Eskim; Lotriga; Lovaza; Omacor; Seacor; TAK-085Latest Information Update: 05 Nov 2023
At a glance
- Originator Pronova Biocare
- Developer Ferrer; GlaxoSmithKline; Kuhnil Pharmaceutical Company; Pronova BioPharma; Reliant Pharmaceuticals; Takeda
- Class Antihyperlipidaemics; Omega 3 fatty acids
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors; Fatty acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertriglyceridaemia; Postmyocardial infarction
- Phase III Cardiovascular disorders
- No development reported Coronary artery disease; Heart failure; Hyperlipidaemia
- Discontinued Atrial fibrillation; IgA nephropathy
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO, Capsule)
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Coronary artery disease in USA (PO)
- 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences